Short Interest: Does Amag Pharmaceuticals Incorporated (NASDAQ:AMAG) Have Gas After Even Less Sellers Involved?

November 24, 2016 - By Linda Rogers   ·   0 Comments

Short Interest: Does Amag Pharmaceuticals Incorporated (NASDAQ:AMAG) Have Gas After Even Less Sellers Involved?

The stock of Amag Pharmaceuticals Incorporated (NASDAQ:AMAG) registered a decrease of 3.1% in short interest. AMAG’s total short interest was 6.08M shares in November as published by FINRA. Its down 3.1% from 6.28 million shares, reported previously. With 579,600 shares average volume, it will take short sellers 11 days to cover their AMAG’s short positions. The short interest to Amag Pharmaceuticals Incorporated’s float is 21.66%. The stock increased 6.76% or $2.1 on November 23, hitting $33.15. About 1.06 million shares traded hands or 21.12% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 14.67% since April 22, 2016 and is uptrending. It has outperformed by 9.26% the S&P500.

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $1.11 billion. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. It has a 95.09 P/E ratio. The Company’s offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena ; services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Insitutional Activity: The institutional sentiment increased to 1.07 in 2016 Q2. Its up 0.24, from 0.83 in 2016Q1. The ratio increased, as 33 funds sold all AMAG Pharmaceuticals, Inc. shares owned while 51 reduced positions. 15 funds bought stakes while 55 increased positions. They now own 42.73 million shares or 1.35% more from 42.16 million shares in 2016Q1.
Connor Clark & Lunn Investment holds 136,025 shares or 0.02% of its portfolio. Alphaone Inv Svcs Ltd Liability Company accumulated 0.49% or 55,014 shares. Pinebridge Invs Ltd Partnership has 4,245 shares for 0.01% of their US portfolio. State Board Of Administration Of Florida Retirement System holds 23,861 shares or 0% of its portfolio. Credit Suisse Ag last reported 41,611 shares in the company. Arcadia Invest Mgmt Mi has 825 shares for 0.01% of their US portfolio. Diam last reported 0.09% of its portfolio in the stock. Lsv Asset Management owns 268,837 shares or 0.01% of their US portfolio. Signalpoint Asset Mgmt Ltd Liability Co last reported 0.2% of its portfolio in the stock. Systematic Finance Lp has 0.02% invested in the company for 73,985 shares. Cap Fund Management Sa, a France-based fund reported 20,733 shares. Guggenheim Cap Limited Liability Company accumulated 0.01% or 86,688 shares. The Georgia-based Invesco Ltd has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). The United Kingdom-based Blackrock Limited has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Ameritas Inv Partners Inc reported 1,000 shares or 0% of all its holdings.

Insider Transactions: Since October 20, 2016, the stock had 0 insider purchases, and 1 sale for $122,462 net activity. 4,938 shares with value of $122,462 were sold by Krop Julie on Thursday, October 20.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Out of 6 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. AMAG Pharmaceuticals has been the topic of 16 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The company was initiated on Thursday, January 21 by Barclays Capital. The firm has “Buy” rating by Jefferies given on Tuesday, August 18. The firm has “Buy” rating by Needham given on Thursday, October 27. The company was reinitiated on Thursday, September 3 by Deutsche Bank. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Buy” rating by Jefferies on Thursday, August 11. The rating was downgraded by Raymond James to “Market Perform” on Wednesday, May 4. The firm earned “Hold” rating on Thursday, November 19 by Deutsche Bank. Leerink Swann maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) rating on Wednesday, May 4. Leerink Swann has “Outperform” rating and $40 price target. The stock has “Strong-Buy” rating given by Zacks on Wednesday, August 19. On Wednesday, November 4 the stock rating was maintained by Deutsche Bank with “Hold”.

AMAG Company Profile

AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Firm has a portfolio of services and products with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>